A radiocalibration method with pseudo internal standard to estimate circulating metabolite concentrations

被引:34
作者
Yi, Ping [1 ]
Luffer-Atlas, Debra [1 ]
机构
[1] Lilly Res Labs, Dept Drug Disposit, Indianapolis, IN 46285 USA
关键词
SAFETY TESTING MIST; DRUG METABOLITES; DURATION; TOXICITY;
D O I
10.4155/BIO.10.81
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Background: It has become important for metabolism scientists to identify and quantify prominent circulating human metabolites in order to develop a metabolite safety-qualification package that meets regulatory standards. Often these metabolites cannot be analyzed using traditional bioanalytical methods because a standard is not available. Results: A radiocalibration method is described that can estimate circulating metabolite concentrations in nonradioactive human and animal plasma. The key to this method is application of a pseudo internal standard (PIS) that is present in both radioactive reference and nonradioactive (i.e., unknown) samples. Metabolite exposure in the unknown samples is estimated from measured PIS exposure using a relative molar ratio established between the metabolite and PIS (usually parent drug). Conclusion: Two case studies demonstrate that the method can be used to establish human metabolite safety coverage in animal plasma and method validation is demonstrated by comparing estimated metabolite concentrations in human plasma with concentrations obtained directly using a metabolite calibration curve.
引用
收藏
页码:1195 / 1210
页数:16
相关论文
共 28 条
[1]   Overview of metabolite safety testing from an industry perspective [J].
Anderson, Shelby ;
Knadler, Mary Pat ;
Luffer-Atlas, Debra .
BIOANALYSIS, 2010, 2 (07) :1249-1261
[2]   Predicting Circulating Human Metabolites: How Good Are We? [J].
Anderson, Shelby ;
Luffer-Atlas, Debra ;
Knadler, Mary Pat .
CHEMICAL RESEARCH IN TOXICOLOGY, 2009, 22 (02) :243-256
[3]   Interpretation and Considerations on the Safety Evaluation of Human Drug Metabolites [J].
Atrakchi, Aisar H. .
CHEMICAL RESEARCH IN TOXICOLOGY, 2009, 22 (07) :1217-1220
[4]   Drug metabolites in safety testing [J].
Baillie, TA ;
Cayen, MN ;
Fouda, H ;
Gerson, RJ ;
Green, JD ;
Grossman, SJ ;
Klunk, LJ ;
LeBlanc, B ;
Perkins, DG ;
Shipley, LA .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 2002, 182 (03) :188-196
[5]   Approaches to the Assessment of Stable and Chemically Reactive Drug Metabolites in Early Clinical Trials [J].
Baillie, Thomas A. .
CHEMICAL RESEARCH IN TOXICOLOGY, 2009, 22 (02) :263-266
[6]   A regulatory perspective on issues and approaches in characterizing human metabolites [J].
Davis-Bruno, Karen L. ;
Atrakchi, Aisar .
CHEMICAL RESEARCH IN TOXICOLOGY, 2006, 19 (12) :1561-1563
[7]  
ELLIS MK, 1995, DRUG METAB DISPOS, V23, P102
[8]   Nuclear Magnetic Resonance Spectroscopy as a Quantitative Tool To Determine the Concentrations of Biologically Produced Metabolites: Implications in Metabolites in Safety Testing [J].
Espina, Robert ;
Yu, Linning ;
Wang, Jianyao ;
Tong, Zeen ;
Vashishtha, Sarvesh ;
Talaat, Rasmy ;
Scatina, JoAnn ;
Mutlib, Abdul .
CHEMICAL RESEARCH IN TOXICOLOGY, 2009, 22 (02) :299-310
[9]  
Food and Drug Administration (FDA) Guidance for Industry, 2008, SAF EFF PHAR STUD SU
[10]   Metabolites in Safety Testing: "MIST" for the Clinical Pharmacologist [J].
Frederick, C. B. ;
Obach, R. S. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 (03) :345-350